Trial Profile
A Phase I Dose Finding and Proof-of-concept Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Combination With Standard Dose Cytarabine and Daunorubicin for Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Proof of concept
- 31 May 2019 Results published in the Clinical Cancer Research
- 19 Apr 2019 Status changed from active, no longer recruiting to completed.
- 23 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.